Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 1, 2012, Pages 113-122

  Cioffi, Angela ^a   Italiano, Antoine ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

Chemotherapy; Ecteinascidin; ERCC5; ET 743; Sarcoma; Trabectedin

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; TRABECTEDIN;

BLOOD TOXICITY; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG ACTIVITY; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIOXOLES; DRUG EVALUATION; HUMANS; SARCOMA; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84255167300     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.636353     Document Type: Review

References (64)

1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-11 (Pubitemid 41175678)
2. Casali PG, Jost L, Sleijfer S, et al. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii89-93
3. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-7 (Pubitemid 29022388)
4. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117:1049-54
5. Cheng EY. Surgical management of sarcomas. Hematol Oncol Clin North Am 2005;19:451-70; v (Pubitemid 40797884)
6. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002;7:348-59 (Pubitemid 34919959)
7. OByrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 1999;56:13-23 (Pubitemid 29043891)
8. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;CD003293
9. Bramwell VHC, Anderson D, Charette M; and the members of the cancer care ontario practice guidelines initiative sarcoma disease site group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma 2000;4:103-12
10. Bui-Nguyen B, Ray-Coquard I, Chevreau C, on behalf of the GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol 2011; [Epub ahead of print]
11. Verweij J, Mouridsen HT, Nielssen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201
12. Rinehart KL. Antitumor compounds from tunicates. Med Res Rev 2000;20(1):1-27 (Pubitemid 30027559)
13. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 2006;7:317-28
14. DIncalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9:2157-63
15. Martinez N, Sanchez-Beato M, Carnero A, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005;4:814-23 (Pubitemid 40767126)
16. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105 (Pubitemid 32119366)
17. Martinez EJ, Corey EJ, Owa T. Antitumor activity-and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8:1151-60 (Pubitemid 34029884)
18. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8 (Pubitemid 32319434)
19. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotideexcision repair. Nat Med 2001;7:961-6 (Pubitemid 32756435)
20. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007;104:13062-7 (Pubitemid 351737593)
21. Herrero AB, Martin-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-62 (Pubitemid 44299183)
22. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85
23. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010;11:196-207
24. DIncalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist 2002;7:210-16 (Pubitemid 34651224)
25. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-42 (Pubitemid 32183024)
26. Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. Trabectedin (Yondelis (TM), formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005;23:429-36 (Pubitemid 41160090)
27. van Kesteren C, de Vooght MM, Lopez-Lazaro L, et al. Yondelis trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 2003;14:487-502 (Pubitemid 37083154)
28. Reid JM, Kuffel MJ, Ruben SL, et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002;8:2952-62 (Pubitemid 35025744)
29. DIncalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003;12:1843-53 (Pubitemid 37408131)
30. Brandon EF, Meijerman I, Klijn JS, et al. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005;16:935-43 (Pubitemid 41416084)
31. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005;6:780-9 (Pubitemid 41430719)
32. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-7 (Pubitemid 28496707)
33. Hendriks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999;10:1233-40 (Pubitemid 29533575)
34. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-65 (Pubitemid 32202528)
35. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003;39:1842-51 (Pubitemid 37311179)
36. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-90 (Pubitemid 41103631)
37. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-9 (Pubitemid 41103601)
38. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-84 (Pubitemid 46224235)
39. Le Cesne A, Yovine A, Blay JY, et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs 2011; [Epub ahead of print]
40. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42:1484-90 (Pubitemid 43903160)
41. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001;19(5):1248-55 (Pubitemid 32202527)
42. Demetri GD, Chawla SP, Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase 2 study of two different schedules. J Clin Oncol 2009;27(25):4188-96
43. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9 (Pubitemid 34185394)
44. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ectenascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23(24):5484-92
45. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-732) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602 (Pubitemid 46995623)
46. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20:1439-44
47. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8:449-57
48. Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13:145-53
49. Takahashi N, Li WW, Benerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET743) with doxorubicine and paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7:3251-7 (Pubitemid 32963850)
50. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET743 and doxorubicine in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-8 (Pubitemid 37041346)
51. Blay JY, Von Mehren M, Sommels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin Cancer Res 2008;14:6656-62
52. Cohen RB, Schilder RJ, Cheng J, et al. Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies. J Clin Oncol 2005;23(Suppl):abstract 3074
53. Schoffski P, Taron M, Jimeno J, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011;47:1006-12
54. Gossage L, Madhusudan S. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007;11:361-80 (Pubitemid 350274404)
55. Robert J, Morvan VL, Smith D, et al. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005;54:171-96 (Pubitemid 40693684)
56. Italiano A, Laurand A, Laroche A, et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011; [Epub ahead of print]
57. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004;31(2 Suppl 6):30-6 (Pubitemid 38879420)
58. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two Phase II clinical trials. J Clin Oncol 2010;28:1772-9
59. Fata F, OReilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcom of the scalp or face. Cancer 1999;86:2034-7
60. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-74
61. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-9 (Pubitemid 32730085)
62. Pautier P, Bui Nguyen B, Penel N, et al. Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol 2009;27(15 Suppl):abstract 10527
63. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010;21:1135-7
64. Soini EJ, Garcia San Andres B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol 2011;22:215-23